GHRH agonists and antagonists in brain experiments

MIA-690 in Alzheimer’s models

The MIA-690 study used genetically modified 5XFAD mice. In the Morris water maze, the antagonist reduced escape latency: the time taken to reach the platform. Brain amyloid-beta1-42 and tau filament levels also decreased. In human HCN2 cortical cells exposed to amyloid-beta1-42, the study reported antioxidant and neuroprotective properties.

Those are distinct parts of the experiment: a learning task in mice and work in cultured cells. The human origin of the cells adds no human cognitive outcome. The conjunction of behavioral and tissue findings impresses me, though the leap to a person’s memory remains substantial.

In amyloid-beta1-42-treated human HCN2 cortical cell cultures, the paper also described inhibition of the GHRH–GH–IGF-1 axis. That gives the antagonist a real place in the argument. A blanket preference for greater activity would discard this result before trying to explain it.

MR-409 and unchanged systemic hormones

In the agonist study, MR-409 improved cognitive performance in 5xFAD mice without altering systemic GH and IGF-1. Reduced amyloid-beta deposition, tau phosphorylation and gliosis accompanied the cognitive result.

The same publication included rat hippocampal neural stem cells and human SH-SY5Y cells. GHRH promoted neuronal survival, proliferation and differentiation in those cell experiments and attenuated amyloid-beta-induced toxicity through reported signaling pathways. The cell work and the mouse intervention supply different pieces of the proposed explanation.

For this debate, the unchanged systemic hormones are especially consequential. They leave room for an account of the mouse findings that requires more than a rising blood-hormone concentration. An experiment separating those possible contributions more decisively would command my interest.

Comparing the animal findings

The antagonist report and the agonist report give this comparison its contents. There was no direct contest between these compounds in these papers. Their separate settings call for a direct comparison before any ranking, and the shared direction of the results leaves the mechanistic question open.

My provisional position is fairly demanding: any satisfying explanation needs to accommodate both observations while preserving the differences between the interventions. The broader review of GHRH biology supplies the pharmacological context; it cannot substitute for that missing comparison.

The human cognition question

The animal findings make a good dispute, but the tesamorelin cognition trial asks a different, human question. The participants, intervention and outcomes deserve their own hearing.

An encouraging mouse result is enough to make another experiment worthwhile in my eyes. A decision about protecting an aging person’s mind calls for evidence in people and a serious accounting of consequences. The molecular argument remains fascinating while that larger task is unfinished.